Table 1.
Patient baseline characteristics
| Patient baseline characteristics | ||||
|---|---|---|---|---|
| All | ||||
| pts | % | |||
| histology | mucoepidermoid carcinoma | 18 | 45 | |
| adeno carcinoma | 8 | 20 | ||
| acinic cell carcinoma | 3 | 8 | ||
| squamous cell carcinoma | 2 | 5 | ||
| salivary duct carcinoma | 2 | 5 | ||
| NOS | 2 | 5 | ||
| basal cell-adeno carcinoma | 2 | 5 | ||
| adenosquamous carcinoma | 1 | 3 | ||
| myoepithelial carcinoma | 1 | 3 | ||
| basaloid carcinoma | 1 | 3 | ||
| stage | T 1 | 3 | 8 | |
| T 2 | 5 | 13 | ||
| T 3 | 13 | 33 | ||
| T 4a | 10 | 25 | ||
| T 4b | 7 | 18 | ||
| T 4c | 1 | 3 | ||
| unknown | 1 | 3 | ||
| N+ | 16 | 40 | ||
| M1 | 3 | 8 | ||
| treatment for recurrent disease | 7 | 18 | ||
| site | parotid gland | 20 | 50 | |
| submandibular gland | 5 | 13 | ||
| oropharynx | 3 | 8 | ||
| maxilla | 2 | 5 | ||
| palate | 2 | 5 | ||
| lacrimal gland | 2 | 5 | ||
| paranasal sinus | 2 | 5 | ||
| petrous bone | 2 | 5 | ||
| middle ear | 1 | 3 | ||
| nasopharynx | 1 | 3 | ||
| age | median in years [range] | 60 | 35-80 | |
| follow-up | all, median in months [range] | 25.5 | 2.5-58.4 | |
| alive, median in months [range] | 27.3 | 3-58.4 | ||
| target volume | CTV1 (boost) in ml | 120 | 34-564 | |
| CTV2 (extended target volume) in ml | 424 | 105-1538 | ||
| dose | C12 in GyE [range] | 23.95 | 17.4-24.4 | 2 pts: C12 only with 66 GyE |
| IMRT in Gy [range] | 50 | 42-56.4 | ||
| total in GyE [range] | 74 | 50.4-74.8 | ||